.png)
GLP-1 receptor agonists like Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro) are transforming the way patients manage weight. This comprehensive guide breaks down what GLP-1s are, how they work, who qualifies, and how to get started with E-TeleHub.
GLP-1 receptor agonists are a class of medications originally designed for type 2 diabetes that also aid in weight loss by slowing digestion and curbing appetite.
Ideal candidates are:
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand Names | Ozempic, Wegovy | Mounjaro |
| Dosing Frequency | Weekly | Weekly |
| Dual Mechanism? | No | Yes (GLP-1 + GIP) |
| Avg. Weight Loss | ~15% of body weight | ~22% of body weight |
E-Pharm Hub, LLC (DBA E-TeleHub and E-Tele) partners with independent licensed physician networks, including MDI Medical Group, P.C., to deliver medical services through the E-Pharm Hub, LLC (DBA E-TeleHub and E-Tele) infrastructure. E-Pharm Hub, LLC (DBA E-TeleHub and E-Tele) does not directly provide medical or pharmacy services. Payment does not guarantee a prescription will be written or dispensed, and you are only charged if a prescription is issued. Medical services are rendered by independent providers. Actual medication form and appearance may differ from what is shown.
Information on this website is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. If you have health-related questions or concerns, please consult your doctor. This website is an advertisement for services, not for any specific medication. Disclaimer: Saxenda®, Victoza®, Wegovy®, and Ozempic® are trademarks of Novo Nordisk™, while Mounjaro™ is a product of Eli Lilly and Company™. E-Tele is not associated with or endorsed by these companies or their products. We do not supply these medications. Individuals interested in these products should consult with their licensed healthcare provider or pharmacist. Compounded semaglutide is offered in response to the ongoing FDA Drug Shortage. For up to date information on drug shortage statuses,
please visit: https://www.accessdata.fda.gov/scripts/drugshortages/
